Chondroitin sulfate - Bioiberica

Drug Profile

Chondroitin sulfate - Bioiberica

Alternative Names: Chondroitin sulfate CS b-Bioactive®; Chondroitin sulphate - Bioiberica; Condro-Sorb; Condrosan; Condrosulf (Bioiberica)

Latest Information Update: 16 Nov 2015

Price : $50

At a glance

  • Originator Bioiberica
  • Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
  • Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal disorders; Osteoarthritis; Rheumatic disorders

Most Recent Events

  • 08 Nov 2015 Efficacy data from a phase III trial in Knee Osteoarthritis presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2015)
  • 05 Mar 2015 Launched for Osteoarthritis in Spain (PO)
  • 05 Mar 2015 Registered for Osteoarthritis in Austria, Czech Republic, Finland, Hungary, Italy, Poland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top